Organogenesis Holdings Inc (NASDAQ:ORGO) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.75.

A number of research firms have recently issued reports on ORGO. Credit Suisse Group began coverage on shares of Organogenesis in a report on Monday, August 26th. They issued an “outperform” rating on the stock. Zacks Investment Research upgraded shares of Organogenesis from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a report on Saturday. Finally, BTIG Research set a $12.00 price objective on shares of Organogenesis and gave the company a “buy” rating in a report on Friday, August 9th.

In other news, major shareholder Michael W. Katz bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the purchase, the insider now owns 10,000 shares of the company’s stock, valued at $45,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Avista Capital Managing Member bought 860,900 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $5.99 per share, with a total value of $5,156,791.00. Insiders purchased 1,521,603 shares of company stock valued at $8,499,019 over the last three months. 70.40% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new position in Organogenesis during the second quarter worth $200,000. Bank of New York Mellon Corp bought a new position in Organogenesis during the second quarter worth $210,000. Northern Trust Corp boosted its position in Organogenesis by 134.3% during the second quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock worth $312,000 after purchasing an additional 23,540 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Organogenesis by 36.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 86,495 shares of the company’s stock worth $658,000 after purchasing an additional 23,180 shares during the period. Finally, Moors & Cabot Inc. bought a new position in Organogenesis during the second quarter worth $694,000. 1.70% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ ORGO traded up $0.32 during midday trading on Friday, reaching $8.11. The company’s stock had a trading volume of 303 shares, compared to its average volume of 19,490. The company has a debt-to-equity ratio of 7.65, a current ratio of 1.43 and a quick ratio of 1.07. Organogenesis has a fifty-two week low of $3.56 and a fifty-two week high of $310.90. The stock has a 50 day simple moving average of $7.29 and a 200-day simple moving average of $6.48.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01. The business had revenue of $64.27 million during the quarter, compared to analyst estimates of $64.00 million. Equities research analysts anticipate that Organogenesis will post -0.49 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

See Also: Support Level

Analyst Recommendations for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.